UTHR Q2 2023 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$597M+27.8% YoY

Gross Profit

$532M89.3% margin

Operating Income

$313M52.5% margin

Net Income

$259M43.5% margin

EPS (Diluted)

$5.24

QoQ Revenue Growth

+17.7%

Cash Flow

Operating Cash Flow

$106M

Free Cash Flow

$62M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$6.7B

Total Liabilities

$1.3B

Stockholders' Equity

$5.4B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$597M	$467M	+27.8%
Gross Profit	$532M	$437M	+21.8%
Operating Income	$313M	$202M	+55.3%
Net Income	$259M	$116M	+123.4%

Revenue Segments

Tyvaso

$319M53%

Remodulin

$127M21%

Orenitram

$95M16%

Unituxin

$44M7%

Adcirca

$8M1%

Product and Service, Other

$4M1%

Geographic Segments

UNITED STATES

$562M94%

Non-US

$35M6%